Alzheimer's disease (AD) is associated with deficiencies in cerebrovascular functions, e.g. reduced cerebral blood flow and capillary amyloid angiopathy, both of which are evident during the early phase of AD, thus local hypoxia/ischemia could augment the pathogenesis of AD. There is abundant literature revealing that exposures to hypoxia/ischemia increase the amyloidogenic processing of amyloid-b precursor protein (APP) leading to the accumulation of amyloid-b peptides in brain. This hypoxia-induced response has been attributed to a significant increase in the activities of b-and csecretases, whereas a-secretase activity decreases in hypoxia. Recent studies have indicated that hypoxia-inducible factor-1a (HIF-1a) stimulates the transcription of the bsecretase 1 (BACE1) gene through the hypoxia-response element in the BACE1 promoter. Moreover, HIF-1a protein can directly interact with the c-secretase complex and increase its activity in a non-transcriptional manner. Hypoxia/ischemia also trigger endoplasmic reticulum stress and impair autophagy in brain, which consequently can stimulate the expression of presenilin 1 (PS1) and activate c-secretase. Subsequently, PS1 protein can stabilize HIF-1a protein and in addition, APP intracellular domain peptide is able to induce the expression of HIF-1a. The activation of b-and c-secretases is an evolutionarily conserved hypoxia response, e.g. it is also present in zebrafish. Given that b-and c-secretases have many substrates in addition to APP, one could postulate that AD pathology is a byproduct of the rescue process mediated by these two aspartyl proteinases under hypoxic/ischemic conditions. We will review the recent evidence indicating that vascular dysfunctions can provoke AD pathology by activating b-and c-secretases.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder discovered by Alois Alzheimer over a century ago. There are several hallmarks of AD, e.g. the deposition of extracellular amyloid-b (Ab) plaques and intracellular tau protein tangles in conjunction with many functional disturbances in synapses and mitochondria, vascular disorders, and aberrant changes in microglia and astrocytes (Querfurth and LaFerla 2010; De Strooper and Karran 2016) . Hardy and Higgins (1992) presented the amyloid cascade hypothesis which postulated that the accumulation of Ab was the primary cause of AD. Subsequently, a plethora of studies has been focused on the basic mechanisms of the processing of amyloid-b precursor protein (APP) and its disturbances in AD (De Strooper 2010; Haass et al. 2012) . There are three key proteinases involved in the cleavage of APP; a-, b-, and c-secretases, which split APP into several peptides (Fig. 1) . Functionally, Ab and the APP intracellular domain (AICD) seem to be the most important peptides. Genetic studies have revealed that mutations in APP and presenilin 1 (PS1) and presenilin 2 (PS2), catalytic subunits of c-secretase complex, cause early-onset AD. However, the prevalence of these mutations is < 1% of all AD cases, i.e. most AD patients are late-onset cases. Despite intensive research and many therapeutic approaches, the primary cause of late-onset AD still needs to be clarified. Many criticisms have been raised against the amyloid hypothesis, claiming that disturbances in APP processing are downstream effects to the primary cause of AD (Drachman 2014; Karran and De Strooper 2016) .
The development of neuroimaging techniques has revealed that many brain regions susceptible to AD pathology display a significant decline in cerebral blood flow already at the phase of mild cognitive impairment which precedes AD diagnosis. The results of these non-invasive studies are consistent with the histopathological observations demonstrating that there is an extensive cerebral amyloid angiopathy (CAA) in hippocampus and many regions of cerebral cortex of AD patients (Attems et al. 2004; Jeynes and Provias 2006) . Brain hypoperfusion reduces the delivery of oxygen and glucose, inducing local hypoxia which in turn stimulates Ab production in both endothelial cells and neighboring neurons provoking the generation of CAA. De la Torre (2000) proposed the hypoperfusion-based hypothesis to supplement AD pathogenesis, i.e. critically attained threshold of cerebral hypoperfusion theory. More recently, Pluta et al. (2013a, b) have reported that sporadic AD could be initiated by ischemic episodes which activate APP processing and increase Ab production. There is compelling evidence that hypoxia-inducible factor-1a (HIF-1a) activates both b-and c-secretases, augmenting APP processing and Ab production in hypoxia. It seems that the activation of band c-secretases is an ancient process; it has been involved in the hypoxia-induced rescue response driven by HIF-1a. First, we will shortly describe the vascular dysfunctions present in AD and then examine in detail the mechanisms through which hypoxia/HIF-1a activates both b-and c-secretases and consequently stimulates APP processing. Finally, we will discuss the role of evolutionarily conserved activation of these two aspartyl proteinases in the brain's defence against hypoxic/ischemic insults and how this may be crucial in the generation of AD pathology.
Vascular dysfunction in AD
There is mounting evidence that AD is associated with substantial deficiencies in cerebrovascular function, e.g. (APP) processing during either normoxic or hypoxic conditions. In normoxia, a-secretase is active and most of the APPs are cleaved through the Ab domain thus inhibiting the formation of Ab peptides. Instead, in hypoxia the activities of b-and c-secretases are stimulated whereas a-secretase activity is reduced, which significantly augments the amyloidogenic processing of APP, generating more and more toxic Ab peptides. Hypoxia also stimulates the production of APP intracellular domain (AICD) peptides. It is known that most of the AICD required for transcriptional regulation has been produced through the amyloidogenic APP processing (Belyaev et al. 2010) . EC, extracellular space; IC, intracellular space.
angiopathy of small capillaries, and dysfunction of bloodbrain barrier (BBB) (Farkas and Luiten 2001; Jeynes and Provias 2006; Thal et al. 2008; Zlokovic 2011; Montagne et al. 2016) . Modern neuroimaging techniques have provided new opportunities to examine the regional alterations in microcirculation during the progress of AD pathology (Montagne et al. 2016) . Several reports have indicated that cerebrovascular dysfunction is an early event in AD pathogenesis (Pluta et al. 2013b; Wierenga et al. 2014; Di Marco et al. 2015; Iturria-Medina et al. 2016) and thus one could speculate that local hypoxia/ischemia is an important enhancer of AD pathogenesis rather than a consequence of the pathological changes observed in AD. Moreover, cerebral ischemia can impair cognitive functions, e.g. spatial learning and memory, and aggravate Ab-induced cognitive deficiencies (Kiryk et al. 2011; Li et al. 2011; Cohan et al. 2015) .
Brain hypoperfusion in AD
Recent neuroimaging studies have indicated that cerebral blood flow (CBF) is reduced in many brain regions and hypoperfusion could be a sensitive preclinical marker of AD (Wierenga et al. 2014; Hays et al. 2016; Montagne et al. 2016) . A non-invasive arterial spin labeling (ASL-MRI) technique has been combined with FDG-PET assays to compare region-specific perfusion data with local metabolic activity. For instance, Verclytte et al. (2016) examined earlyonset AD patients and demonstrated that the areas suffering the most significant hypoperfusion were located in the parietal lobes, the right posterior cingulate cortex, and the frontal lobes. The reduction in glucose metabolism displayed a more global pattern than the changes observed in CBF, although there appeared to be hypoperfused areas in the frontal lobes which did not display evidence of hypometabolism. Many studies have also demonstrated that CBF is reduced in patients with mild cognitive impairment even though in some brain regions of these patients there appeared to be an increase in resting CBF (Wierenga et al. 2014; Hays et al. 2016; Wirth et al. 2016) . This might suggest that at first the vulnerable regions can increase their CBF in order to maintain cognitive functions. Currently, it seems that brain hypoperfusion linked to local hypoxia or even ischemia can precede sporadic AD, although it is difficult to detect transient hypoxia/ischemia in microcirculation with noninvasive assessments in human brain. Brain hypoperfusion in AD might be caused by the development of CAA involving the deposition of Ab peptides in brain capillaries. There are also studies indicating that endothelium-mediated mechanisms can induce vascular dysfunction in AD (Di Marco et al. 2015) . For instance, increased homocysteine levels impair CBF by reducing the production of the vasodilatory nitric oxide (Toda and Okamura 2016) . It is known that homocysteine is a significant risk factor for AD (Seshadri et al. 2002) , probably through the generation of amyloid angiopathy.
Alzheimer's disease is the most common cause of dementia associated with cerebrovascular dysfunction. Another disorder is vascular dementia (VaD), also called vascular cognitive impairment or multi-infarct dementia (O'Brien and Thomas 2015) . Even though AD and VaD share several clinical features, their differential diagnosis requires brain imaging and/or post-mortem assessments. (Banerjee et al. 2016; Kalaria 2016) . Pathologically, VaD displays microinfarcts and lacunar infarcts, hemorrhagic lesions, fibroid necrosis, arteriosclerosis, and hyalinosis (Kalaria 2016) . Many cardiovascular risk factors, e.g. hypertension, and dyslipidemia, also are risk factors for VaD (Frances et al. 2016) . Given that VaD's pathological changes differ from those encountered in AD, the role of APP processing has remained unresolved in its pathogenesis. However, CAA is present in both VaD and AD, which suggests that APP processing has been modified although AD-like plaques are not normally present in VaD. Different types of microinfarcts are common in VaD indicating that ischemic episodes are involved in the pathogenesis of VaD. Currently, it is known that ischemic brain insults affect the activation of APP processing secretases, enhancing Ab accumulation (Pluta et al. 2013a) .
Cerebral amyloid angiopathy CAA is one hallmark of AD, i.e. the deposition of Ab peptides within the walls of cerebral capillaries disturbs the homeostasis of neighboring neurons (Attems et al. 2004; Jeynes and Provias 2006; Thal et al. 2008) . The appearance of capillary CAA correlates with the accumulation of Ab peptides inside vulnerable brain regions, e.g. hippocampus and cerebral cortex, and thus it reflects the pathological progress of AD and could be a consequence of increased neuronal and endothelial Ab generation. In turn, capillary CAA augments the local hypoperfusion which consequently aggravates brain hypoxia/ischemia and thus further promotes neuronal Ab production. Interestingly, Roher et al. (2003) demonstrated that the atherosclerosis in the circle of Willis is a risk factor for AD, thus reducing the blood perfusion to the brains of AD patients. There are many cardiovascular risk factors which can decrease brain capillary perfusion. Moreover, it is known that cholinergic fibers from basal forebrain can control regional cerebral blood flow (Sato et al. 2001a) . Lojkowska et al. (2003) reported that rivastigmine, a cholinesterase inhibitor, increased brain blood flow in both AD and VaD patients indicating that a part of therapeutic effects of cholinesterase inhibitors may be mediated via improved cerebrovascular blood flow. It is also known that hypoxic/ischemic insults to cultured capillary endothelial cells stimulate b-secretase 1 (BACE1) expression and activity that subsequently increases amyloidogenic processing and Ab production (Bulbarelli et al. 2012; Brambilla et al. 2015; Muche et al. 2015) . The second scenario proposes that reduced capillary blood flow provokes hypoxia/ischemia that could trigger a vicious cycle by activating APP processing in endothelial and smooth muscle cells, subsequently leading to the accumulation of Ab peptides within capillary walls. This kind of endothelial origin of CAA could aggravate local neuronal hypoxia and consequently activate the APP processing secretases of neurons, augmenting Ab accumulation in the brains of AD patients. The putative endothelial origin of CAA is in agreement with many observations indicating that hypoperfusion and capillary endothelial dysfunction have a fundamental role in the pathogenesis of AD (Kelleher and Soiza 2013; Di Marco et al. 2015) .
Hypoxia/ischemia stimulates amyloidogenic Ab production
Cerebral hypoperfusion with expanding CAA generates local hypoxia, even ischemia, which disturbs energy metabolism and induces adaptive responses through the expression of HIF-1a (Correia and Moreira 2010) . Several experimental studies have revealed that the exposure of brains to either hypoxia or ischemia activated amyloidogenic APP processing, stimulating the production of Ab peptides and the accumulation of amyloid plaques (Pluta et al. 2013a; Shiota et al. 2013; Villarreal et al. 2014) . Many studies have also reported that hypoxia elevated the expression level of APP in the affected brain regions. Hypoxia also facilitated AD pathogenesis e.g. in APP23 transgenic mice (Sun et al. 2006) as well as in double transgenic (APP/PS1) mice (Gao et al. 2013) . It is also known that traumatic brain injury increases Ab generation in human brains (Marklund et al. 2014) , probably through vascular dysfunction. There is an abundant literature indicating that hypoxia in vitro also stimulates the amyloidogenic APP processing and increases the generation of Ab peptides in neuronal cells (Sun et al. 2006; Zhang et al. 2007; Shiota et al. 2013) and astrocytes (Pluta 2002) as well as vascular endothelial cells (Bulbarelli et al. 2012; Muche et al. 2015) . These observations clearly indicate that hypoxia/ischemia can stimulate the amyloidogenic processing of APP in different cell types in the brain and subsequently augment AD pathogenesis.
The accumulation of Ab peptides in the hypoxic brain is attributable to disturbances in the balance between different APP processing through either the non-amyloidogenic asecretase or amyloidogenic b/c-secretase pathways (Fig. 1 ). In addition, the extent of the degradation of Ab as well as its removal by phagocytosis and/or clearance through the BBB can affect the accumulation of Ab peptides into brain. For instance, hypoxia inhibits the expression and activity of neprilysin, an amyloid-degrading peptidase, in rat cortical neurons and this can also augment the accumulation of Ab peptides in the affected regions (Fisk et al. 2007 ). HIF-1a transcription factor binds to the promoter of neprilysin gene and suppresses its transcription (Mitra et al. 2013 ). In addition, hypoxia disturbs the function of BBB, suppressing the clearance of toxic compounds, such as Ab, from the brain (Zlokovic 2011) . Given that hypoxia inhibits a-secretase and strongly stimulates the amyloidogenic b/c-secretase pathway ( Fig. 1) , it seems likely that the deposition of Ab is a result of the activation of amyloidogenic processing, as we will discuss below.
Hypoxia inhibits activity of a-secretase
The disintegrin and metalloproteinase domain-containing protein (ADAM) family members ADAM10 and ADAM17 are the two major APP cleaving enzymes acting at the a-site of the protein (Fig. 1 ). These protein sheddases evoke a nonamyloidogenic processing of APP by cutting the Ab domain of the APP. Suh et al. (2013) demonstrated that two missense mutations in the prodomain of ADAM10 reduced the activity of ADAM10 and enhanced the amyloidogenic, bsite processing of APP leading to the accumulation of Ab plaques. Interestingly, there are many studies which have revealed that hypoxia significantly decreased the expression and activity of both ADAM10 and ADAM17 proteins in neuronal cells (Webster et al. 2002; Marshall et al. 2006) and microvascular smooth muscle cells (Auerbach and Vinters 2006) . APP is not the only substrate for a-secretases there are many other important membrane proteins, e.g. KLOTHO, MEPRIN b, and NOTCH1, which could have a role in AD pathogenesis (Saftig and Lichtenthaler 2015) . The action of a-secretases produces an extracellular sAPPa fragment which exerts several neuroprotective functions, e.g. it protects against ischemic insults and glutamate neurotoxicity (Chasseigneaux and Allinquant 2012) . It also has many neurotrophic properties e.g. it stimulates neuritogenesis, synapse formation, and memory retention. Moreover, sAPPa peptide inhibits the activity of BACE1 preventing the amyloidogenic processing of APP (PetersLibeu et al. 2015) . Not only does hypoxia down-regulate the function of a-secretases, it simultaneously enhances a shift in APP processing toward the amyloidogenic pathway during hypoxic/ischemic conditions.
Hypoxia induces expression of b-secretase
The BACE1 is an aspartyl sheddase which cleaves APP at its b-site, not only in vitro but also in vivo (Fig. 1) . BACE1 is highly expressed in the nervous system and it is known to act on several substrates, both within and outside of the brain (Vassar et al. 2014) . During APP processing, the cleavage by BACE1 precedes that of c-secretase in the generation of Ab peptides. Given that BACE1 has a fundamental role in the amyloidogenic APP processing and its expression is significantly increased in AD, there are many drug discovery programs attempting to obtain potent inhibitors of BACE1 (Vassar et al. 2014) . Although BACE1 inhibitors can prevent the production of Ab peptides and the accumulation of amyloid plaques, it has been noted that the chronic administration of BACE1 inhibitors exerts many harmful effects, e.g. it disturbs myelination and interferes with synaptic plasticity; not surprising, in view of the wide range of physiological functions controlled by BACE1 (Barao et al. 2016) . Since endosomes are the major site for BACE1-mediated APP cleavage, it is interesting to note that endosomal sorting is impaired in both hypoxic conditions (Wang et al. 2009 ) and Alzheimer's disease (Xu et al. 2016) .
There is convincing evidence that hypoxic insults increase the expression and activity level of BACE1 not only in cultured neuronal cells but also in the affected brain regions (Sun et al. 2006; Zhang et al. 2007; Guglielmotto et al. 2009; Li et al. 2009 ). Global ischemia and stroke also augmented the expression of BACE1 (Zhiyou et al. 2009; Pluta et al. 2013a Pluta et al. , 2016b Kocki et al. 2015) . In addition, hypoxia enhanced the expression of BACE1 in brain capillary endothelial cells (Bulbarelli et al. 2012) . Many studies have reported that the generation of Ab and sAPPb peptides can be increased by hypoxic/ischemic insults, indicating that BACE1 has a crucial role in the APP processing. Sun et al. (2006) demonstrated that the promoter of BACE1 gene contains a functional hypoxia-responsive element (HRE) which facilitates the transcription of BACE1 gene in both cultured neuronal cells and brains of APP23 transgenic mice. Hypoxia increased the b-site cleavage of APP which augmented the formation of amyloid plaques and evoked memory deficits in transgenic APP23 mice. Zhang et al. (2007) also reported that HIF-1a controlled the expression of BACE1 gene through the HRE binding element. They observed that the level of BACE1 protein was significantly down-regulated in the brains of mice with a conditional knockout of HIF-1a. Hypoxia, as well as AD, is associated with energy metabolic deficiencies and oxidative stress. Velliquette et al. (2005) demonstrated that the reduction in energy metabolism by 2-deoxyglucose and 3-nitropropionic acid induced the expression of BACE1 in the brains of wild-type mice and APP transgenic (Tg2576) mice. Energy deficiency also aggravated the cerebral amyloidogenesis in the Tg2576 mice. Moreover, oxidative stress increased the expression and activity of BACE1 in both cultured neuronal cells and rat brains (Guglielmotto et al. 2009 (Guglielmotto et al. , 2010 . It is known that the BACE1 gene is tightly regulated at both transcriptional and post-transcriptional levels (Sun et al. 2012) . It seems that the activation of BACE1 is included in the HIF-1a-driven hypoxia response although the exact role of APP processing in brain hypoxia needs to be revealed. Given that the regulatory BACE-PS axis of APP processing is present in zebrafish embryos (Moussavi Nik et al. 2012) , it does seem that APP processing has functions in the hypoxia response which have been conserved throughout the course of evolution.
Hypoxia activates c-secretase
The c-secretase is an intramembrane-cleaving protease complex which cuts the APP after its cleavage by bsecretase, thus producing Ab peptides (Fig. 1) . Initially, csecretase cleaves the C-terminal fragment of APP at the boundary between membrane and cytoplasm releasing AICD peptide (Weidemann et al. 2002; Morishima-Kawashima 2014) . This e-cleavage generates the AICD peptide which is a transcription factor to be translocated into the nucleus (Konietzko 2012 ). Subsequently, c-secretase breaks down the remaining part of C-terminal fragment of APP through a stepwise trimming process generating an array of Ab peptides of different lengths (Morishima-Kawashima 2014; Bolduc et al. 2016) . The two major peptides are Ab40 and Ab42. The Ab40 peptide has many neuroprotective properties, whereas Ab42 peptide is prone to aggregate and it seems to be toxic. The c-secretase complex is composed of four proteins: presenilin 1 or 2 (PS1 or PS2), nicastrin (NCT), anterior pharynx-defective-1 (APH-1), and presenilin enhancer 2 (PEN2) (Lu et al. 2014) . The PS subunits are the catalytic domains in the c-secretase complex and thus the complex has also been called a presenilin complex. The presenilin/c-secretase complex can cleave many single-pass membrane proteins, in addition to APP (Haapasalo and Kovacs 2011) . Presenilins have also many other functions which are not related to the c-secretase activity, e.g. in calcium homeostasis and protein trafficking (Duggan and McCarthy 2016) . Mutations in PS1, PS2, and APP have been linked to the early onset form of familial AD. However, the mechanism determining how these mutated proteins affect the function of c-secretase complex is still unclear although it seems that PS1 mutations can potentiate the cleavage process to generate the toxic Ab42 peptides rather than Ab40 forms (Fernandez et al. 2014) .
Epigenetics
The function of c-secretase complex is tightly regulated since there are distinct control mechanisms through its four subunits (Gertsik et al. 2015) . There is abundant evidence that hypoxia/ischemia increase the expression and activity of c-secretase in the brain and neuronal cultures (Pennypacker et al. 1999; Li et al. 2009; Pluta et al. 2013a; Kocki et al. 2015) . The GC-rich promoters of PS1 and PS2 genes do not contain HRE sites, i.e. they are not directly under the control of HIF-1a. However, the promoter of human APH-1A gene does contain HIF-1a binding sites and the expression of APH-1 is increased by hypoxia (Wang et al. 2006) . Interestingly, APH-1 is a scaffold protein which has a crucial role in the assembly and activation of c-secretase complex (Lee et al. 2004) . Liu et al. (2016) demonstrated that chronic hypoxia decreased the global methylation level of genomic DNA in the frontal cortex of transgenic APP swe /PS1 dE9 mice, probably attributable to a decrease in the expression of DNA methyltransferase 3b. They also reported that the methylation levels of CpG sites in the promoters of PS1, PEN2, and NCT were significantly reduced, whereas those of APP, BACE1, and APH-1A were not affected. Correspondingly, chronic hypoxia increased the protein expression of APH-1A, PEN2, and NCT, but not that of PS1. They also revealed that inhibition of DNMTs increased the protein levels of APH-1A, NCT, PS1, and PEN2 in normoxic mouse N2a cells. These studies indicate that hypoxia might control the expression of the subunits of c-secretase complex and subsequently increase the activity of c-secretase and Ab production via epigenetic regulation. Moreover, the modification of DNA methylation level by the S-adenosylmethionine/S-adenosylhomocysteine cycle controls the expression of PS1 and Ab production in neuronal cultures (Fuso et al. 2005) . There are studies indicating that S-adenosylmethionine/S-adenosylhomocysteine cycle is disturbed in AD (Zhuo et al. 2011 ) but its role in amyloidogenic APP processing still needs to be clarified.
ER stress
Both hypoxia and ischemia are potent inducers of endoplasmic reticulum (ER) stress in the brain (Xin et al. 2014; Xu et al. 2015) . Increased ER stress is also associated with the pathogenesis of AD (Salminen et al. 2009 ); this might be a consequence of the presence of mild local hypoxia and disturbances in the maintenance of proteostasis. Badiola et al. (2011) demonstrated that the PERK-eIF2a-ATF4 and IRE1-X-box binding protein 1 (XBP1) pathways, two major coordinators of the ER stress-induced unfolded protein response (UPR), became activated following oxygen-glucose deprivation in rat cortical cultures as well as after hypoxia/ ischemia in neonatal mouse cortical tissues. Many other studies have also revealed that the hypoxia/ischemia-induced UPR involves the activation of the PERK and IRE1 pathways in the brain and neuronal cells (DeGracia and Montie 2004; Bickler et al. 2015) . The ATF4 and XBP1 are transcription factors which can switch on the UPR, thus preventing acute neurodegeneration. Interestingly, Mitsuda et al. (2007) demonstrated that ATF4 could bind to the promoter regions of the human PS1 gene and induce its transcription during nutritional deprivation of leucine and lysine. Recently, they observed that the expression of ATF4 was increased in the cerebral cortex of transgenic APP23 mice (Hayakawa et al. 2015) . Moreover, PERK-eIF2a signaling increased BACE1 expression and amyloidogenesis in transgenic Tg2576 (O'Connor et al. 2008 ) and 5xFAD (Devi and Ohno 2014) mice. It is known that ER stress triggers autophagy, a process intended to cleanse the cell from accumulated proteins. However, recent studies have revealed that ER stress can also suppress autophagy through different mechanisms, e.g. XBP1 can enhance the degradation of FOXO1, a major inducer of autophagy proteins in neurons (Rashid et al. 2015) . Given that autophagy is impaired in AD (Nixon and Yang 2011; Salminen et al. 2013) , there are studies indicating that the impairment of autophagy stimulated the expression of PS1 as well as increased c-secretase activity and Ab generation (Ohta et al. 2010; Cai et al. 2015) . It seems that ER stress and impaired autophagy provoke UPR which triggers the expression of BACE1 and PS1, thus enhancing the amyloidogenic APP processing.
Alternative splicing of PS2
The PS1/c-secretase and PS2/c-secretase complexes have different functional properties, e.g. they act in specialized cellular compartments and they have dissimilar enzyme processivity of substrates, also in the processing of APP (Acx et al. 2014; Meckler and Checler 2016) . The PS1/c-secretase complexes are broadly distributed in neurons, also present in plasma membrane, whereas PS2/c-secretase complexes are located in intracellular compartments, such as trans-Golgi network, recycling endosomes, and the late endocytic compartment (Vetrivel and Thinakaran 2006; Meckler and Checler 2016) . For instance, PS2 complexes are able to modulate ER-mitochondria Ca 2+ crosstalk by interacting with mitofusin 2 (Filadi et al. 2016) . Recently, Sannerud et al. (2016) demonstrated that PS2/c-secretase complexes are targeted to the acidic late endosome/lysosomal (LE/LYS) compartment through PS2 phosphorylation-induced binding to the AP-1, an endosomal sorting protein. They also revealed that the PS2/c-secretase complex present in the LE/LYS generated the major part of the toxic intracellular Ab pool. In 1999, Sato et al. (2001b) characterized an alternative splice variant of the PS2 gene lacking exon 5 in the brains of sporadic AD patients (present in 70% of AD patients vs. 17.6% of age-matched controls). Interestingly, they also demonstrated that hypoxia, but not many other stresses, induced the generation of PS2 splice variant (PS2V) splice variant in neuroblastoma cells. Later, Sato et al. (2001b) reported that the PS2V protein increased the production of Ab peptides and moreover, it augmented the vulnerability of neurons to ER stress by impairing the generation of UPR. The aberrant splice variant has been found to be expressed in the pathologically affected neurons in the hippocampus and temporal cortex in AD patients. Subsequently, Higashide et al. (2004) identified a cis-acting sequence in the PS2 pre-mRNA which mediated the exon 5 skipping of PS2 under hypoxic stress. Manabe et al. (2007) demonstrated that the high mobility group A protein 1a (HMGA1a) was the trans-acting factor which triggered the exon 5 splicing of the PS2 pre-mRNA. It is known that the induction of HMGA1a is a common response to hypoxia/ oxidative stress (Moussavi Nik et al. 2011) . The mechanism of increased amyloidogenic APP processing by PS2V needs to be clarified, especially since brain ischemia was able to increase the expression of PS2 in rat cortex (Pluta et al. 2016a) .
Protein interactions
The assembly and activation of c-secretase complex is dependent on (i) cofactors, i.e. NCT, APH-1, and PEN2, (ii) several interacting proteins, e.g. c-secretase activating proteins (GSAPs), voltage-dependent anion channel 1 (VDAC1), and HIF-1a, and (iii) lipid microdomains called lipid rafts (Ehehalt et al. 2003; Wakabayashi et al. 2009; Hur et al. 2012; Gertsik et al. 2015; Inoue et al. 2015) . Moreover, APP has its own interactome which probably affects the processivity of APP (Bai et al. 2008) . Screening studies on the proteins interacting with the c-secretase complex have revealed an array of proteins, some of which increase APP processing rather than Notch activation (Hur et al. 2012; Inoue et al. 2015) . Inoue et al. (2015) characterized distinct GSAPs, e.g. VDAC1 and syntaxin-binding protein 1, which were largely expressed in the human brain and showed a neuron-specific interaction with c-secretase. VDAC1 is an interesting GSAP since hypoxia induces a truncation of VDAC1 protein; this increases metabolic capacity and resistance to hypoxic cell death in cancer cells (Mazure 2016) . Manczak et al. (2013) revealed that a reduced expression of VDAC1 in transgenic VDAC1 +/À mice was associated with a decreased cerebral expression of APP, PS1, PS2, and BACE1. In contrast, the expression of VDAC1 was found to be enhanced in the brain tissues of human AD and transgenic AD mice (Cuadrado-Tejedor et al. 2011) . The mechanism explaining how VDAC1 could act as a GSAP needs to be clarified. Another interesting GSAP is HIF-1a protein which can interact with the c-secretase complex and increase its activity in a non-transcriptional manner (Villa et al. 2014) . De Gasperi et al. (2010) demonstrated that the binding of PS1 protein to HIF-1a increased the stability of HIF-1a protein and thus the level of hypoxia-induced response. They also observed that the PS1 FAD mutation (M146V) impaired the activation of HIF-1a. Interestingly, Kaufmann et al. (2013) revealed that the AICD peptide, a product of the c-secretase cleavage of APP, stimulated the transcription of the HIF-1a gene. These studies clearly indicate that the APP/c-secretase pathway is involved in the control of the hypoxia response.
Lipid rafts
Lipid rafts of membranes are potent regulators of amyloidogenic APP processing (Ehehalt et al. 2003; Cheng et al. 2007; Vetrivel and Thinakaran 2010) . Lipid rafts are specialized membrane microdomains enriched with sphingolipids and cholesterol capable of undergoing distinct protein-protein and lipid-protein interactions (Quinn 2010; Simons and Sampaio 2011) . The rafts float freely in membranes and they are involved in the assembly of protein complexes in specific membrane micro-environments and subsequently in their trafficking to different cellular compartments. There is mounting evidence that the homeostasis of lipid rafts is altered in AD patients (Martin et al. 2010; Zhou et al. 2014; Diaz et al. 2015) . Bhattacharyya et al. (2013) demonstrated that APP could be palmitoylated (palAPP) and then the palAPP was targeted into lipid rafts. It is known that the palmitoylation of proteins is required for the recruitment of proteins into the cholesterol-rich lipid rafts. Bhattacharyya et al. (2013) also revealed that palmitoylation enhanced BACE1-mediated APP processing and Ab production in lipid rafts. Marquer et al. (2011) observed that the cholesterol exposure of cells triggered the clustering of APP and BACE1 proteins which were transferred into lipid rafts and consequently relocated into intracellular compartments after endocytosis. The c-secretase complex was associated with lipid rafts in the post-Golgi and endosomal compartments (Vetrivel et al. 2004) . The activity of c-secretase was augmented in lipid rafts, probably because of the presence of cholesterol and other lipids of rafts (Osenkowski et al. 2008) . Urano et al. (2005) observed that the inhibition of cholesterol synthesis by statins significantly reduced the association of c-secretase complex with lipid rafts. Given that hypoxia modifies the structure and composition of lipid rafts (Botto et al. 2008; Danza et al. 2013) , it is evident that hypoxia might increase the amyloidogenic processing of APP by altering the presence and activity of BACE1 and c-secretase in lipid rafts. Danza et al. (2013) revealed that hypoxia induced the translocation of active PS1 protein into lipid rafts together with its substrate, NOTCH3 protein, in prostate cancer cells. They also observed that hypoxia increased the cholesterol level and promoted the formation of larger cluster structures in the lipid rafts. Moreover, Oda et al. (2010) demonstrated that oxidative stress, linked to hypoxia/ischemia, increased the protein level of PS1 in lipid rafts as well as augmented Ab production in human SH-SY5Y neuroblastomas. It would be important to clarify whether the hypoxia-induced alterations of lipid rafts can enhance amyloidogenic APP processing.
Activation of b-and c-secretases is an evolutionarily-conserved hypoxia response
Phylogenetic studies on APP gene have revealed an ancient multigene family with a number of homologous amyloid precursor-like proteins (APLP) (Coulson et al. 2000; Shariati and De Strooper 2013; Tharp and Sarkar 2013) . The members of this family are highly conserved type-1 transmembrane proteins which are targets of proteolytic processing. The ancestral APP-like proteins are present in Caenorhabditis elegans (APL-1) and Drosophila (APPL) but not in prokaryotes, yeasts, or plants (Shariati and De Strooper 2013) . After the gene duplication event which took place about half a billion years ago during the Cambrian period, the APP and APLP genes first appeared in fishes and amphibians. The mammalian genome contains three genes, i.e. APP, APLP1, and APLP2 genes, which are functionally more or less redundant although each member does undertake some specific functions because of divergences in their transcriptional regulation (Shariati and De Strooper 2013) . The exact molecular functions of APP are still elusive although the members of APP/APLP lineage have displayed properties, indicating that they might be activated during cell adhesion (Coulson et al. 2000) . Moreover, the intracellular AICD peptide, generated through APP processing, is a transcription factor for a set of genes, thus emphasizing the physiological significance of APP processing (Konietzko 2012) . It is known that APP/APLP proteins are involved in neural development, e.g. in neurite outgrowth and synaptogenesis; it seems that they have specific trophic functions during embryogenesis (Zheng and Koo 2006; Dawkins and Small 2014) , even in the zebrafish development (Joshi et al. 2009 ).
The b-and c-secretases are aspartyl proteinases and are members of a large superfamily of aspartic proteinases. The evolutionary origin of these two APP processing enzymes is much more ancient than that of APP/APLP family (McMains et al. 2010; Moore et al. 2014; Smolarkiewicz et al. 2014) . et al. 2010) indicating that the function of PS/c-secretase has been largely conserved during the course of evolution. In Dictyostelium, presenilin is localized within ER and it is indispensable for phagocytosis (McMains et al. 2010; Ludtmann et al. 2014) . In addition, presenilin proteins have crucial non-catalytic functions as scaffold protein throughout evolution (Otto et al. 2016) . The human PS1 can even rescue the multicellular development of presenilin defective Dictyostelium discoideum (Ludtmann et al. 2014) . Given that the divergence of Dictyostelium from the human lineage occurred over one billion years ago (Otto et al. 2016) , it seems apparent that b-and c-secretases are involved in several fundamental activities in organisms which are not linked to the APP processing.
The zebrafish is an ideal model in which to study the evolutionary aspects in the pathogenesis of AD, since the zebrafish possesses orthologous genes to the major components involved in APP processing (Newman et al. 2014) . The zebrafish lineage appeared during the Cambrian period when the O 2 level increased in the atmosphere and the metazoan radiation took place (Taylor and McElwain 2010) . Simultaneously, the complexity of the HIF pathway expanded, e.g. HIF-1a and HIF-2a genes are present in the genome of zebrafish (Nikinmaa and Rees 2005) . Moreover, given that the epigenetic regulation of chromatin landscape is dependent on oxygen via the 2-oxoglutarate-dependent dioxygenases (Salminen et al. 2015) , it seems likely that the role of epigenetics in gene expression became augmented during the Cambrian period. Interestingly, Moussavi Nik et al. (2012) revealed that hypoxia induced the transcription of bace1, ps1, ps2, and app genes in zebrafish embryos as well as in the brains of adult zebrafish. This study clearly demonstrated that the induction of the BACE1-PS1/PS2-APP regulatory axis by hypoxia has been conserved through evolution which indicates that APP processing is involved in some advantageous functions as the brain attempts to combat hypoxia/ischemia. Recently, Moussavi Nik et al. (2015) reported that both the human PS2V and the zebrafish ortholog, PS1IV, stimulated the activity of c-secretase and APP cleavage. Moreover, the hmga1 gene, an ortholog to human HMGA1A, is also a hypoxia-inducible gene in the zebrafish genome provoking an alternative splicing of the presenilin gene product (Moussavi Nik et al. 2011) . Moussavi Nik et al. (2015) observed that the zebrafish truncated ortholog of PS2V could suppress the UPR response in zebrafish, as described in human neuronal cells. Recently, Ebrahimie et al. (2016) revealed that the knock-down of the PS1IV variant in hypoxia (and thus reduced c-secretase activity) affected the gene expression of many crucial regulatory networks, e.g. heat-shock response, ER stress, calcium homeostasis, protein synthesis, and inflammation. This indicates that PS/c-secretase controls an integral network of regulatory genes during hypoxia. In conclusion, the studies with zebrafish clearly demonstrated that the hypoxia responsiveness of BACE1 and PS1/PS2 genes has been conserved during evolution and the effects of these two aspartyl proteinases are not only involved in APP processing but they have more global neuroprotective functions during hypoxia/ischemia.
Is AD pathology a byproduct of hypoxia-induced rescue process in human brain? Hypoxia/ischemia is an environmental stress but oxygen availability can also be reduced in many pathological conditions, e.g. in cerebral amyloid angiopathy and ischemic stroke. Hypoxia activates the expression of HIF-1a/HIF-2a transcription factors which organize the transcription of hundreds of genes involved in the defence of the organism (Semenza 2012; Ratcliffe 2013) . Moreover, hypoxia can epigenetically stimulate the expression of target genes by activating hypoxia-inducible histone lysine demethylases (Salminen et al. 2016) . Although oxygen deficiency is a master inducer of HIF-1a, many other stress signals can also induce the stabilization of HIF-1a protein, also during normoxic conditions. This process is called pseudohypoxia (Salminen et al. 2016) . For instance, inflammatory cytokines, oxidative stress, ceramide synthesis, and impaired function of Krebs cycle can increase the level of HIF-1a protein in cells. It is known that NF-jB signaling, induced by inflammatory factors as well as oxidative stress, is capable of driving the expression of BACE1 and PS1/PS2 (Rossner et al. 2006; Guglielmotto et al. 2010 Guglielmotto et al. , 2012 Moussavi Nik et al. 2012) . Interestingly, many of these factors are involved in the pathogenesis of AD. The hypoxia-responsive activation of BACE1/PS/APP pathway is not restricted only to AD-related angiopathy but appears also in other brain pathologies where blood circulation has been impaired, e.g. in ischemia/stroke (Popa-Wagner et al. 1998; Pluta et al. 2013a ) and brain trauma (Scott et al. 2016) .
It seems that the hypoxia-induced activation of membrane aspartyl proteinases (i.e. b-and c-secretases) has a beneficial role as a part of the hypoxia response, since their hypoxiaresponsiveness has been conserved for hundreds of millions of years. Moreover, HIF-1a directly induces the transcription of BACE1, whereas HIF-1a protein activates the c-secretase complex by binding to it in the membrane (Villa et al. 2014) . BACE1 protein and the components of c-secretase are commonly expressed in human tissues and in this respect it differs from APP, which is mostly expressed in brain (Human Protein Atlas). Both BACE1 and c-secretases can cleave a multitude of membrane proteins, e.g. c-secretase has at least 89 substrates (Haapasalo and Kovacs 2011) . For instance, PS1/c-secretase cleaves NOTCH1 protein releasing a Notch intracellular domain (NICD). NICD is a transcription factor known to induce the expression of several hypoxiaassociated genes, e.g. those controlling angiogenesis (Benedito and Hellstr€ om 2013). In brain, NICD enhances synaptic plasticity and neurogenesis and can augment regeneration (Alberi et al. 2013) . Notch1 signaling also increases astrocytic proliferation and astrocyte activation after hypoxia (Zhang et al. 2015) as well as it can stimulate microglial activation in hypoxic conditions (Yao et al. 2013) . BACE1 inhibitor studies have indicated that BACE1 has a crucial role in developmental processes, e.g. it controls myelination and immune responses (Venugopal et al. 2008) . Given that hypoxia is a fundamental regulator during embryogenesis and cancer, it is no surprise that the activation of HIF-1a is associated with the function of b-and c-secretases.
In brain, the hypoxia-induced processing of APP has been conserved during evolution, at least from zebrafish to humans. There has appeared a domain-specific sequence variation with evolution in the APP, affecting the aggregation properties of Ab peptides (Tharp and Sarkar 2013) . Moreover, only the Ab peptide cleaved from the APP but not the fragment released from APP-like proteins is prone to aggregate. The Ab domain (bA4 region) contains a conserved metal-binding motif (HD) (e.g. for copper, iron, and zinc) which is present in many catalytic centers of ancient enzymes (Miklos and Zadori 2012) . It is still not understood why the Ab peptide of some species does not aggregate in vivo; probably this is because of sequence variations or differences in the intracellular milieu. For instance, the mouse and rat Ab peptides do not form amyloid aggregates (Tharp and Sarkar 2013) . The exact function of APP is also unclear although there has been intense research in this field.
There are observations that APP could act in cell adhesion or it might have a role in cellular signaling (Deyts et al. 2016) . Deyts et al. (2016) have described in detail the properties of APP, explaining its function as a receptor molecule which might signal downstream via its peptide metabolites, i.e. AICD, Ab, sAPPa/b. There are controversial observations on the function of AICD, i.e. many studies indicate that AICD can induce apoptosis and AD-related neuronal pathologies (Ghosal et al. 2009; Ohkawara et al. 2011) , whereas others have indicated that AICD can induce the expression of APP (von Rotz et al. 2004) , clearly a positive feedback response, and elevate the levels of neprilysin (Pardossi-Piquard et al. 2005) , a potent cleaving enzyme of Ab peptides. Ceglia et al. (2015) demonstrated that AICD was able to limit Ab production and restore memory deficits in transgenic AD mice. AICD inhibited WAVE1 expression, which is an anchoring protein and inducer of myelination. It is evident that all of the cofactors and post-translational signals controlling APP/AICD-dependent transcription are not known and especially their context-dependent role needs to be clarified. However, APP knockout mice are highly susceptible to cerebral ischemia (Koike et al. 2012) , indicating that APP and its fragments have important roles in the response to hypoxia. Robinson et al. (2014) reported that the APP/AICD pathway stimulated the expression of PGC-1a and thus augmented mitochondrial respiration. In Caenorhabditis elegans, APL-1, an APP-related protein, is essential for controlling viability e.g. acting through metabolic pathways in collaboration with the DAF16/FOXO pathway, known for its function in growth and longevity regulation (Ewald et al. 2012 ).
Conclusions
There is compelling evidence indicating that hypoxia/ ischemia activates b-and c-secretases and consequently increases Ab production in the brain. This is an ancient response to hypoxia, since it is present in e.g. zebrafish. HIF1a factor has a fundamental role in the activation of these two aspartyl proteinases indicating that the cleavage of membrane proteins is involved in the hypoxia-induced rescue process. There is widespread expression of BACE1 and the components of c-secretase in different tissues, not only in the tissues containing the APP, which suggests that these two proteinases could be involved in hypoxic/ischemic responses in other tissues than the brain. Considering the fact that the role of APP in the pathogenesis of AD still needs to be clarified, it is possible that the processing of distinct target proteins other than APP by c-secretase might augment AD pathology in hypoxia/ischemia insults. There are some candidates cleaved by c-secretase which have been linked to AD pathology, e.g. Notch signaling (Alberi et al. 2013) , neuregulin-1/ErbB4 pathway (Chaudhury et al. 2003; Sardi et al. 2006) , and alcadein (calsyntenin) proteins (Takei et al. 2015) . Vascular dysfunctions are present during the early phase of AD pathogenesis, probably attributable to the hypoperfusion of brain. This could aggravate the onset of CAA and enhance the progress of AD pathology since local hypoxia increases amyloidogenic APP processing and promotes the deposition of Ab within capillaries. It is tempting to speculate that AD is a byproduct of hypoxia/ischemiainduced activation of b-and c-secretases in the human brain.
